

Index

A

- Abuse disorders
 - neglect (*see* Child neglect)
 - physical abuse (*see* Child physical abuse)
 - sexual abuse, 195–197
- Acid-fast bacilli (AFB), 56
- Acid–Schiff stain, 58
- Acute erythrodermic, 8
- Acute gastrointestinal GVHD, 109
- Acute generalized exanthematous pustulosis (AGEP), 8
 - differential diagnosis, 92
 - erythema, 91
 - hypocalcemia and hypoalbuminemia, 92
 - laboratory, 91–92
 - medications, 92
 - physical examination, 91
 - pustular miliaria, 93
 - pustular psoriasis, 93
 - skin biopsy, 92
 - treatment, 93
- Acute GVHD
 - bone marrow HSCT, 102
 - clinical presentation, 104
 - differential diagnosis, 103, 104
 - HLA, 103
 - laboratory investigations, 103
 - morphologic patterns, 103
 - physical exam, 102–103
 - prognosis, 105
 - risk factors, 103
 - skin biopsy, 104
 - stage IV (*see* Stage IV acute GVHD)
 - treatment plan, 103, 105
- Acute hemorrhagic edema of infancy (AHEI)
 - diagnosis, 226, 227
 - differential diagnosis, 227
 - etiology, 227
 - GI symptoms, 227
 - laboratory investigations, 226
 - physical exam, 226, 227
 - upper respiratory infection, 227
- Acute lymphoblastic leukemia (ALL), 26, 152, 233
- Acute myelogenous leukemia (AML), 62
- Acute myeloid leukemia (AML), 102, 152, 229
- Acute urticaria
 - blood eosinophils, 73
 - bullae, 72
 - dermatographism, 71, 72
 - differential diagnosis, 71, 73
 - etiology, 73
 - food and medication, 73
 - histopathology, 73
 - immunologic/non-immunologic pathways, 72
 - laboratory investigations, 71
 - management, 71
 - physical examination, 71
 - severe pruritus, 71
 - treatment, 73–74
 - vasculitides, 73
- Acyclovir, 21, 25, 26
- Adjuvant therapy, 105
- Alanine aminotransferase (ALT), 194
- Alemtuzumab, 108
- Allergic/irritant contact dermatitis
 - causes, 10
 - chlorhexidine, 11

- Allergic/irritant contact dermatitis (*cont.*)
 cocamidopropyl betaine, 10
 delayed-type IV hypersensitivity reaction, 10
 diaper dermatitis, 10
 features, 10
 iodine (Betadine), 11
 laboratory investigations, 10
 natural history, 10
 neomycin, 10
 Neosporin, 9
 prevalence, 10
 resources, 10
 tape, 11
 time and exposures, population level, 10
American Academy of Pediatrics (AAP), 194
Amyopathic DM, 128
Antibacterial and antifungal cover, 234
Anti-nuclear antibody (ANA), 79
Anti-Ro Ab, 141
Antithymocyte globulin (ATG), 108
Anti-tumor necrosis factor (TNF) agents, 108
Aplasia cutis congenita (ACC)
 abnormalities, 135
 congenital localized absence of skin, 136
 diagnostics, 135
 disruption in skin development, 135
 EB, 136
 heterogeneous condition, 135
 limb abnormalities, 136
 malformations and genetic syndromes, 136
 management, 135
 monitoring, 136–137
 MRI, brain, 135
 patient history, 134
 physical exam, 134–135
 scalp lesions, 136
 teratogens, 136
 treatment, 136–137
 X-ray, skull, 135
Appearance, pulse, grimace, activity, respiration (APGAR), 148
Aspartate aminotransferase (AST), 194, 196
Atopic dermatitis (AD), 19
 chronic inflammatory condition, 3
 evidence-based treatment guidelines, 3
 infection, 5–6
 Methicillin-sensitive Staph Aureus, 2
 moderate, 2
 PCP, 1
 pediatric, 3
 primary care pediatricians, 3
 pruritus, 4
 surveillance cultures, 6
 systemic therapies, 2, 4
 topical treatments, 2–4
Autoimmune bullous diseases, 83
Autoimmune skin disorders (collagen vascular)
 JDM, 125–128
 SLE, 122–125
 still's disease, 119–122
Autoinflammatory disorders, 236
Azole antifungals, 58
- B**
Bacterial infections
 ecthyma gangrenosum, 35–38
 meningococcemia, 43–46
 SSSS (*see* Staph scalded skin syndrome (SSSS))
 TSS (*see* Toxic shock syndrome (TSS))
Bacterial sepsis, 64
Bad diaper rash, 195
Benign cutaneous polyarteritis nodosa (BPAN), 223
B-lactam antibiotic, 49
Bleach baths, 5
Bleeding disorders, 194
Blue rubber bleb nevus syndrome (BRBNS), 186
Body surface area (BSA), 83, 105
Bone marrow transplant
 HSCT, 102, 103, 106, 109
 IBMTR, 107
BRBNS. *See* Blue rubber bleb nevus syndrome (BRBNS)
Bullous pemphigoid (BP)
 bacterial infections, 216
 differential diagnosis, 216
 histopathologic findings, 218
 history, 215
 laboratory parameters, 215–216
 pathogenesis, 217
 physical examination, 215
 pruritus, 217
 subepidermal blistering, 218
 treatment, 218
 vaccination, 217
- C**
Calcineurin inhibitors (CNI), 105
CANDLE syndrome, 236
CAT. *See* Cutaneous visceral angiomas, with thrombocytopenia (CAT)
Cefepime, 62
Central nervous system (CNS), 24

- CH. *See* Congenital hemangiomas (CH)
- Chickenpox, 27
- Child neglect
- asthma and mild atopic dermatitis, 197
 - burns, 200
 - differential diagnosis, 199
 - eczema, 198
 - inflicted cigarette burns, 199
 - laboratory parameters, 199
 - physical exam, 198–199
 - signs of physical abuse, 200
 - treatment, 200–201
- Child physical abuse
- AAP, 194
 - bleeding disorders, 194
 - differential diagnosis, 193
 - laboratory parameters, 193
 - occult injuries, 194
 - petechial rash and lethargy, 191
 - physical exam, 192
 - primary care pediatrician, 192
 - skeletal survey, 194
 - skin injuries, 193
 - treatment, 194, 195
- Child sexual abuse
- bad diaper rash, 195
 - bleeding diathesis, 196
 - dermatitis, 196
 - ecchymoses and petechiae, 196
 - genital/anal examinations, 196, 197
 - laboratory parameters, 195
 - physical examination, 195–197
 - skull fracture, 195
 - STIs, 197
 - subdural hematoma, 195
 - treatment, 197
- Childhood bullous pemphigoid, 213
- Chlorhexidine, 10, 11
- Chronic atypical neutrophilic dermatosis, 236
- Chronic GVHD (cGVHD), 103
- bone marrow HSCT, 109
 - classification, 111
 - diagnosis, 110
 - HSCT, 111
 - ichthyosiform (*see* Ichthyosiform cGVHD)
 - lichen planus-like lesions, 111
 - median time, 111
 - morphologies, 110
 - nonsclerotic manifestations, 111
 - physical exam, 109–110
 - risk factors, 111
 - sclerotic, 111
 - treatment plan, 110–112
- Coalescing erythematous papules, 126
- Cocamidopropyl betaine, 10
- Community acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA)
- abscesses, 48
 - ACME, 48
 - cellulitis, 48
 - diagnosis, 47
 - history, 46
 - laboratory results, 47
 - leukocidins, 48
 - physical examination, 47
 - populations, 48
 - PSM, 48
 - risk factors, 47
 - skin abscesses, 48
 - skin cultures, 48
 - treatment, 47, 49
- Complete blood count (CBC), 154
- Computed tomography (CT), 156
- Congenital fibromatosis, 166
- Congenital heart block (CHB), 141, 142
- Congenital hemangiomas (CH), 183
- Congenital melanocytic nevi (CMN)
- baseline MRI, 139
 - classification system, 138
 - diagnostic investigations, 137
 - differential diagnosis, 138
 - ectopic locations, 138
 - history, 137
 - imaging, 137
 - malignancy, 139
 - malignant melanoma, 139
 - management, 139
 - medical risks, 138, 139
 - NCM, 138
 - physical examination, 137, 138
 - risks association, 137
 - satellite lesions, 138
 - treatment, 137, 139
- Corticosteroid treatment, 58
- Coxsackie virus, 17
- Coxsackie virus A6 (CVA6), 20
- Cutaneous candidiasis
- antibiotic therapy, 54
 - blood cultures, 56
 - congenital candidiasis, 55
 - diagnosis, 54, 56
 - differential diagnosis, 54, 56
 - fatal systemic infections, 55
 - fetal skin, 55
 - genetic disease, 56
 - infants, 54
 - laboratory parameters, 54
 - low birth weight neonates, 56

- Cutaneous candidiasis (*cont.*)
 in neonates, 55
 physical examination, 54, 55
 pregnancy, 54
 premature neonate, 55, 56
 risk of infection, 55
 treatment, 54
 types, 55
- Cutaneous visceral angiomatosis, with
 thrombocytopenia (CAT).
See Multifocal vascular lesions
- Cyclophosphamide, 125, 128
- Cyclosporine, 8
- D**
- Deficiency of Interleukin 1 Receptor
 antagonist (DIRA), 8
- Dermatitis
- AD (*see* Atopic dermatitis (AD))
 - allergic/irritant contact
 (*see* Allergic/irritant contact dermatitis)
 - diaper (*see* Diaper dermatitis)
 - facial (*see* Facial dermatitis)
 - herpetiformis, 28, 213
 - interface, 115
 - pustular, 231
 - spongiotic, 21, 231
- Diaper dermatitis
- barrier breakdown, 16
 - concomitant infections, 16
 - contact, 16
 - coxsackie virus, 17
 - diaper cream, 16
 - erosive, 15
 - gentle skin care, 16
 - immature nature, newborn skin, 16
 - infant with pustules and erythema, 14, 15
 - irritants, 16
 - Langerhans cell histiocytosis, 16, 17
 - low-grade superinfection, 16
 - management, 14
 - psoriasis, 17
 - streptococcal and staphylococcal
 infections, 16
 - topical cholestyramine, 16
 - treatment, 15
 - wound healing environment, 16
 - zinc deficiency, 16, 17
- DIC. *See* Disseminated intravascular
 coagulation (DIC)
- DiGeorge syndrome, 12, 14
- Diphtheria, tetanus, acellular pertussis
 (DtaP), 215
- Direct fluorescence antibody (DFA), 25
- Direct immunofluorescence (DIF), 79, 209
- Disseminated cutaneous zoster, 28
- Disseminated disease, 25
- Disseminated intravascular coagulation
 (DIC), 179
- Disseminated systemic zygomycosis
- AML, 62
 - 1,3-beta-D-glucan, 65
 - blood cultures, 65
 - causative organisms, 65
 - differential diagnosis, 64
 - fusarium infections, 65
 - galactomannan, 65
 - infection, 65
 - laboratory parameters, 62–64
 - medications, 62
 - morbidity and mortality, 64
 - neutropenic fever, 64
 - physical examination, 62, 63
 - primary and secondary cutaneous
 disease, 65
 - real-time PCR, 65
 - serologic fungal antigens, 65
 - tissue biopsy, 65
 - treatment, 66
- Drug reaction with eosinophilia and systemic
 symptoms (DRESS), 43, 84
- cutaneous morphologies, 90
 - differential diagnosis, 88, 90
 - drug detoxification enzyme, 90
 - erythematous macules and papules, 88, 89
 - laboratory parameters, 88
 - myocarditis, 90
 - pathogenesis, 90
 - physical examination, 88
 - treatment, 90–91
 - trimethoprim-sulfamethoxazole, 88
- Drug-induced hypersensitivity syndrome
 (DIHS), 89
- Drug-induced TEN, 107
- Dystrophic Epidermolysis Bullosa Research
 Association (DEBRA), 210
- E**
- Ecchymoses, 192, 193, 195, 196
- Ecthyma gangrenosum
- biopsy, 37
 - cutaneous infection, 37
 - diagnosis, 38
 - differential diagnosis, 37
 - erythematous indurated nodule, 35, 36
 - laboratory parameters, 36

- pathology, 36, 37
 - physical examination, 36
 - red macules, 37
 - treatment, 37, 38
 - Eczema, 198
 - Eczematous eruptions
 - blood cultures, 11
 - CBC, 14
 - diagnosis, 12, 14
 - differential diagnosis, 12
 - genetic disorders, 12, 13
 - genetic syndromes, 12
 - GVHD, 14
 - hepatosplenomegaly, 11
 - infants, 11, 12
 - labs, 11
 - SCID, 14
 - seborrheic dermatitis, 12
 - treatment, 14
 - Electroencephalogram, 25
 - Endocarditis, 64
 - Engraftment syndrome, 104
 - Enterococcus faecalis*, 11
 - Enterotoxins-a, 39
 - Enterotoxins-b, 39
 - Enterotoxins-c, 39
 - Enteroviral exanthem
 - AD, 19
 - diagnosis, management and sequelae, 21–23
 - differential diagnosis, 21, 22
 - presentation, 20–21
 - scattered vesicles and erosions, legs, 20
 - Enterovirus, 20, 28
 - Eosinophilic folliculitis, 8
 - Epidermolysis bullosa (EB), 136
 - autoimmune blistering disorders, 208
 - Darier's sign, 208
 - differential diagnosis, 207
 - histological findings, 209–210
 - history, 206
 - laboratory parameters, 206–207
 - newborn with blisters, 209
 - physical examination, 206
 - treatment, 210
 - Epidermolysis bullosa acquisita (EBA), 208
 - Epidermophyton floccosum, 58
 - Epstein–Barr virus (EBV), 30, 87
 - Erythema multiforme (EM), 75
 - allergic rhinitis, 76
 - cephalexin, 76
 - fixed drug eruption, 79, 80
 - laboratory parameters, 77
 - mycoplasma serology and PCR, 79
 - oral mucosa, 78
 - papules and plaques, 77
 - pathognomonic morphologic features, 77
 - physical examination, 77
 - prodromal fever and malaise, 78
 - SJS/TEN, 78, 79
 - treatment, 80
 - viral exanthems, 79
 - young-adults, 78
 - Erythema nodosum (EN)
 - arthralgias, 95
 - cellulitis, 95
 - children, 95
 - differential diagnosis, 95
 - erythema induratum (nodular vasculitis), 96
 - laboratory parameters, 94
 - leukocytoclastic vasculitis, 96
 - leukocytosis, 96
 - numerous erythematous, 94
 - pathogenesis, 95
 - physical examination, 94
 - septal panniculitis, 96
 - skin biopsy, 94
 - streptococcal pharyngitis, 95
 - treatment, 96
 - type I diabetes, 93
 - Erythema/poikiloderma, 128
 - Erythematous and purpuric macules, 106
 - Erythematous macules and papules, 102
 - Erythematous malar rash, 123, 124
 - Erythematous patches, dorsal hands, 123, 124
 - European Registry of Severe Cutaneous Adverse Reaction study group, 89
 - Evanescient rash, 121
 - Extracorporeal photopheresis (ECP)
 - acute GVHD, 108, 109
 - cutaneous cGVHD, 111, 112
- F**
- Facial dermatitis
 - anxiety, 201
 - differential diagnosis, 202
 - laboratory parameters, 201
 - MRSA, 201
 - physical examination, 201, 202
 - SISLs, 202, 203
 - skin biopsy/diagnostic testing, 203
 - skin lesions, 203
 - symptoms, 201
 - treatment, 203–204
 - Fluorescence in situ hybridization (FISH), 154
 - Folliculocentric prominence, 104

- Fungal infection in pediatrics
 - cutaneous candidiasis, 54–56
 - Disseminated systemic Zygomycosis, 62–66
 - Majocchi's granuloma, 56–58
 - systemic mycoses: primary cutaneous, 58–62

G

- G6PD deficiency, 214
- Gastrointestinal pathology, 56
- Generalized lymphadenopathy, 121
- Genetic syndromes, 12
- Giant CMN. *See* Congenital melanocytic nevi (CMN)
- Glomovenous malformations (GVM), 186
- Glucose transporter-1 protein (GLUT-1), 184
- GLUT-1. *See* Glucose transporter-1 protein (GLUT-1)
- Goeckerman therapy, 8
- Gomori methenamine-silver, 58
- Gottron's papules, 127
- Gottron's sign, 127
- Graft-versus-host disease (GVHD)
 - acute (*see* Acute GVHD)
 - chronic (*see* Chronic GVHD)
 - ichthyosis (*see* Ichthyosiform cGVHD)
 - vs. prophylaxis, 102
- Gram stain, 56
- Granulocyte-colony stimulating factor (G-CSF), 230
- Granuloma gluteal infantum, 15
- Griseofulvin, 58
- GVM. *See* Glomovenous malformations (GVM)

H

- Hand, foot and mouth disease (HFMD), 20
- Heliotrope rash, 127
- Hematologic malignancies, 61
- Hematopoietic stem cell transplant (HSCT)
 - ALL, 106
 - bone marrow, 102, 103
 - cGVHD, 109, 111
 - classic signs and symptoms, acute GVHD, 104
 - engraftment syndrome, 104
 - ichthyosiform cutaneous GVHD, 113, 116
 - pediatric GVHD, 103
 - post-allogeneic, 105
- Hemophagocytic lymphohistiocytosis (HLH), 122
- Hemophilia disease, 193
- Henoch–Schönlein purpura (HSP), 96, 193, 213
 - diagnosis, 225

- differential diagnosis, 225
- direct immunofluorescence, 225
- laboratory investigations, 224
- MRSA abscesses, 224
- perivascular inflammatory infiltrate, 225
- physical exam, 224
- renal disease, 226
- skin biopsy, 225
- treatment, 226
- trimethoprim-sulfamethoxazole, 224
- Hepatosplenomegaly, 11, 121
- Herpes simplex, 8
- Herpes simplex virus (HSV), 62, 207, 208
- Herpes zoster/shingles, 27
- Horner's syndrome, 158
- H-syndrome (SLC29A3 mutation), 236
- Human enterovirus infection, 43
- Human leukocyte antigen (HLA), 83, 90, 103, 111
- Hydroxychloroquine, 125
- Hyper IgE Syndrome (HIES), 12–14
- Hypercalcemia, 133, 134
- Hypocalcemia, 8, 92

I

- Ichthyosiform cGVHD
 - clinical course, 115–116
 - diagnosis, 113, 114
 - laboratory parameters, 113
 - management, 113
 - nonsclerotic phenotypes, 115
 - physical examination, 113, 114
 - presentation, 113
 - prognosis, 113
 - risk factors, 114
 - skin biopsy, 115–116
 - therapeutic plan, 115–116
- Ichthyosiform scale, 113
- IgA dermatosis, 217
- IH. *See* Infantile hemangiomas (IH)
- Incontinentia pigmenti (IP)
 - CNS, 145
 - dental exam, 144
 - eosinophils, 144
 - gene IKBKG/NEMO, 144
 - genetic testing, 145
 - histopathology, 144
 - history, 142
 - hyperpigmentation, 144
 - hypopigmentation/depigmented lesions, 144
 - laboratory parameters, 143
 - ophthalmic anomalies, 144
 - physical exam, 143

- retinal vasculopathy, 145
 - skin biopsy, 145
 - skin lesions, 144
 - skin manifestations, 144
 - stages, 144
 - X-linked dominant disorder, 144
 - Indirect immunofluorescence (IIF), 79
 - Infantile hemangiomas (IH). *See* LUMBAR syndrome
 - lumbosacral spine, 181
 - perineal, 181
 - VM, 178
 - Infantile myofibromatosis
 - benign tumors, 165
 - biopsy, 164–165
 - clinical types, 166
 - congenital fibromatosis, 166
 - dermal nodules, 166
 - differential diagnosis, 165
 - fibrosis, calcification and hyalinization, 166
 - immunohistochemistry, 165
 - mortality rates, 166
 - multicentric disease, 167
 - nodular fasciitis, 166
 - physical examination, 164
 - pink-red bump, 164, 165
 - treatment, 167
 - visceral organs, 166
 - Interleukin-2 receptor antibodies, 108
 - International Bone Marrow Transplant Registry (IBMTR) criteria, 107
 - International League Against Rheumatism (ILAR) criteria, 121
 - International Neuroblastoma Risk Group Staging System (INRGSS), 159
 - International Neuroblastoma Staging System (INSS), 159
 - Intraepidermal and subcorneal pustules, 231
 - Intravenous immunoglobulin (IVIG), 85
- J**
- Jacquet's erosive diaper dermatitis, 15
 - Japanese Research Committee on Severe Cutaneous Adverse Reaction group, 89
 - Juvenile dermatomyositis (JDM)
 - amyopathic, 128
 - calcinosis/dystrophic calcification, 128
 - children, 128
 - cutaneous manifestations, 127
 - diagnosis, 127
 - electromyography studies/muscle biopsy, 128
 - features, 127
 - history, 125
 - interstitial lung disease, 127
 - laboratory outcomes, 127
 - physical examination, 126–127
 - swallowing symptoms and voice changes, 127
 - treatments, 127
- K**
- Kaposiform hemangioendothelioma (KHE)
 - KMP, 175
 - laboratory parameters, 175
 - MRI, 175
 - retroperitoneum, 175
 - right posterior shoulder and back, 174
 - treatment, 176
 - Kasabach–Merritt phenomenon (KMP), 175, 176, 179
 - Kawasaki disease (KD), 40, 83, 122
 - Klippel–Trenaunay syndrome, 179
 - KMP. *See* Kasabach–Merritt phenomenon (KMP)
- L**
- Lactate dehydrogenase (LDH), 64
 - Leiner's phenotype, 12, 13
 - Leukemia cutis
 - abdominal ultrasound, 151
 - APGAR, 148
 - biopsy, 153
 - blueberry muffin phenotype, 150
 - bone marrow, 152
 - chemotherapy, 154
 - Coomb's test, 150
 - CSF, 151
 - cytarabine and anthracyclines, 154
 - cytogenetic analysis, 153
 - dermal erythropoiesis, 153
 - differential diagnosis, 148
 - flow cytometry, skin cells, 151
 - immunohistochemical stains, 153
 - immunohistochemistry/cytogenetics, 153
 - lab outcomes, 150–152
 - lesions scattered, trunk, 148, 149
 - malignant myeloid/lymphoid blasts, 152
 - MLL, 154
 - multiple violaceous nodules, 148, 149
 - neoplastic infiltrative processes, 150
 - peripheral smear, 150–151
 - physical examination, 148
 - prognosis, 153
 - punch biopsy, left leg lesion, 151

- Leukemia cutis (*cont.*)
 skin trauma, 152
 temporary/permanent spontaneous remission, 153
 TORCH infections, 150, 152
 tumor lysis syndrome, 152
 VMA and HVA, 152
- LIC. *See* Localized intravascular coagulopathy (LIC)
- Lichen sclerosus-like lesions may, 112
- Limb abnormalities, 136
- Linear IgA bullous disease (LABD) of childhood
 autoimmune disorder, 214
 bullous eruptions, 213
 chronic bullous disease, 212
 differential diagnosis, 212, 213
 histopathologic findings, 214
 history, 211
 laboratory parameters, 212
 pathogenesis, 213
 physical examination, 211
 pruritic papulovesicular eruption, 213
 string of pearls, 213
 treatment, 214
- Lines of Blaschko, 144
- Lipoatrophy, 236
- Liposomal amphotericin, 231
- Lipschütz ulcer (LU)
 diagnosis and management, 31
 differential diagnosis, 31
 left labia, 29, 30
 presentation, 30
- Localized intravascular coagulopathy (LIC)
 coagulopathy, 179
 GI involvement, 186
- LUMBAR syndrome
 genitourinary/perineal IH, 181
 gluteal cleft, 177, 180
 and PELVIS syndromes, 161, 181
 peri-anal bleeding, 179
 propranolol therapy, 181
 red vascular plaques, 181
 and SACRAL, 181
- M**
- Macrophage-activation syndrome (MAS), 122, 125
- Maculopapular/exanthematous, 87
- Majocchi's granuloma
 antifungals, 58
 clinical forms, 58
 culture/KOH evaluation, 58
 dermatophyte infection, 58
 description, 57
 diagnosis, 57, 58
 differential diagnosis, 57, 58
 follicular invasion, 58
 fungal stains, 58
 granulomatous inflammation, 58
 neutrophilic dermal abscesses, 58
 pathogenesis, 58
 physical examination, 57
 red scaling rash, 56
 subcutaneous granulomatous, 58
 trauma, 58
 treatment, 57, 58
 Trichophyton rubrum, 58
- Mammalian target of rapamycin (mTOR)
 inhibitors, 108
- Melanocytic nevus
 CMN (*see* Congenital melanocytic nevus (CMN))
- Meningococemia, 46–49
 CA-MRSA (*see* Community acquired methicillin-resistant *Staphylococcus aureus* (CA-MRSA))
 ceftriaxone, 44
 differential diagnosis, 45
 intravenous fluids, 44
 laboratory outcomes, 44
N. meningitidis, 45
 physical exam, 44, 45
 post-exposure prophylaxis, 45
 prophylaxis, 46
 purpura fulminans, 45, 46
 treatment, 46
- Meropenem, 231
- Mesenchymal stem cells (MSCs), 108
- Metaiodobenzylguanidine (MIBG), 156
- Methicillin-resistant *Staphylococcus aureus* (MRSA), 5, 40, 46–49, 201, 236
- Methicillin-sensitive *Staphylococcus Aureus* (MSSA), 2, 5
- Methotrexate, 8
- Mixed lineage leukemia (MLL), 154
- MLT. *See* Multifocal lymphangioendotheliomatosis (MLT)
- Morbilliform drug eruption
 cutaneous adverse drug reactions, 86
 dermatomyositis, 85
 differential diagnosis, 86, 87
 erythematous macules and papules, 86, 87
 histopathology, 87
 laboratory, 86
 physical examination, 86
 treatment, 87
- Moxibustion, 199

- Mucormycosis, 61, 62. *See also* Primary cutaneous mucormycosis
- Multifocal lymphangioendotheliomatosis (MLT), 185, 186
- Multifocal vascular lesions
 differential diagnosis, 186
 GI bleeding, 184
 laboratory parameters, 185
 MLT, 186
 violaceous papules and plaques, 184, 185
- Mycophenolate, 125
- Mycophenolate mofetil (MMF), 80, 108, 112, 218, 223
- Mycoplasma pneumoniae*, 78
- Mycoplasma*-induced rash and mucositis (MIRM), 79
- N**
- Narrow band ultraviolet B phototherapy (nbUVB), 112
- National Institute of Allergy and Infectious Diseases (NIAID), 5
- National Institute of Health Consensus Development Project, 111
- National Institutes of Health (NIH), 5
- National Marrow Donor Program, 103
- Neisseria meningitidis*, 45, 46
- Neonatal herpes simplex virus (HSV)
 differential diagnosis, 25
 presentation, 23–25
 treatment and management, 25–26
 widespread cropped erosions, 23, 24
- Neonatal lupus
 family history, 140
 laboratory parameters, 140–141
 NLE (*see* Neonatal lupus erythematosus (NLE))
 physical exam, 140
 ranges, 141
 treatments, 141
- Neonatal lupus erythematosus (NLE)
 cardiomyopathy, 142
 CHB, 141, 142
 cutaneous lesions, 141
 cutaneous manifestations, 141
 diagnosis, 141
 hematologic, 142
 intravenous steroids, 142
 IVIG, 142
 kidney and central nervous system, 142
 low-to-mid potency topical steroids, 142
 maternal autoantibodies, 141
 owl eye/eye mask facial rash, 141
 pediatric rheumatology and dermatology, 142
 SSA/SSB antibody, 141
 sun protection, 142
- Netherton's syndrome, 12, 14
- Neuroblastoma
 adrenal medulla, 158
 benign ganglioneuroma, 159
 biopsy, 156, 157
 children, 158
 cytogenetics, 157
 diagnosis, 156
 differential diagnosis, 155
 immunohistochemical markers, 159
 INRGSS, 159
 laboratory values, 156–157
 left plantar foot, 155
 liver and skin, 158
 MIBG, 158
 MRI spine, 157
 neuropil, 159
 pediatric tumors, 158
 physical examination, 155
 raccoon eyes, 158
 right labia majora, 155, 156
 Tc 99 scan, 157
 treatment, 160
- Neurocutaneous melanosis (NCM), 137–139
- Neutropenia, 37
- Neutrophilic dermatosis
 idiopathic, 232
 infection, 231
 noninfectious skin conditions, 232
 PG, 238
 treatment range, 233
 with lipodystrophy, 236
- Neutrophilic urticarial dermatosis (NUD), 73
- Nikolsky's sig, 210
- Non-involuting congenital hemangioma (NICH), 183, 184
- Non-steroidal anti-inflammatory drug (NSAIDs), 223
- O**
- Occult injuries, 194
- Omenn syndrome, 12, 14
- Opioid analgesia, 235
- Opportunistic fungal infection, 55, 61, 64, 66
- P**
- Panniculitis
 ALL, 233
 anti-inflammatory agents, 236

- Panniculitis (*cont.*)
- biopsies, 235
 - causes, 235
 - classification systems, 236
 - differential diagnoses, 234, 235
 - histopathological examination and biopsy, 236
 - investigations, 234
 - lipoatrophy, 236
 - nonspecific symptoms, 235
 - patient progress, 234–235
 - physical examination, 234
 - treatment, 234, 236
 - ultrasound, 235
- Pathergy, 239
- Pathological skin picking, 203
- Pediatric GVHD, 103
- Pediatric Oncology Group staging system, 162
- Pediatrics
- fungal infection (*see* Fungal infection in pediatrics)
- PELVIS syndrome, 181
- Pentostatin, 108
- Petechiae, 192
- Pityriasis lichenoides, 202
- Pneumocystis prophylaxis, 62
- Polyarteritis nodosa (PAN)
- BPAN, 223
 - cutaneous features, 223
 - differential diagnosis, 222, 223
 - laboratory investigations, 222
 - NSAIDS, 223
 - and nodules, 221
 - physical examination, 221–222
 - prognosis, 223
 - purple tender plaques, 221
 - skin biopsy, 223
 - streptococcal infections, 223
 - types, 223
- Polymerase chain reaction (PCR), 21, 25
- Post-herpetic neuralgia (PHN), 28
- Potassium hydroxide (KOH)/PAS, 56
- Primary cutaneous mucormycosis
- Aspergillus* and *Rhizopus*, 61
 - bone marrow biopsy, 58
 - causative agents, 61
 - CBC, 58
 - diagnosis, 60, 61
 - differential diagnosis, 61
 - DM and systemic immunosuppression, 61
 - H&E stain, 60
 - hematologic malignancies, 61
 - laboratory parameters, 59–60
 - morphology, 61
 - mucormycosis, 61
 - paronychia, 61
 - physical examination, 59
 - risk factor, 61
 - tissue biopsy, 61
 - treatment, 60–62
- Propranolol, 181, 184
- Pruritic disorders, 199
- Pruritus, 27
- Pseudomona aeruginosa*, 36, 37
- Pseudoverrucous papules, 15
- Pustular psoriasis
- acitretin and isotretinoin, 8
 - and acute erythrodermic, 8
 - biologic therapies, 8
 - calcium, 9
 - cyclosporine, 8
 - dermatologists, 8
 - development, 6
 - diagnosis, 7
 - differential diagnosis, 8
 - erythrodermic/exfoliative, 7
 - flares, 7
 - Goeckerman therapy, 8
 - hospitalization and systemic treatment, 7
 - hypocalcemia, 8
 - labs, 6
 - management, 8
 - methotrexate, 8
 - nails, 7
 - physical examination, 6, 7
 - skin biopsy and laboratory testing, 8
 - systemic steroids, 7, 9
 - topical triamcinolone, 8
 - treatment, 8
- Pyoderma gangrenosum (PG)
- clinical presentation, 238
 - dense neutrophilic infiltrate without vasculitis, 238, 239
 - diagnosis, 237, 238
 - differential diagnosis, 238
 - inflammatory bowel disease, 239
 - infliximab, 240
 - lab investigation, 237
 - morphology, 239
 - necrotic plaque, 237, 238
 - pathergy, 239
 - patient history, 236
 - physical examination, 236, 237
 - skin biopsy, 238
 - treatment, 238, 239

R

- Raccoon eyes, 158
- Rapid plasma reagin (RPR), 29–30
- Rapidly involuting congenital hemangioma (RICH)
 - GLUT-1, 184
 - heart failure/liver failure, 184
 - hypochoic subcutaneous mass, 183
 - laboratory parameters, 183
 - NICH, 183
 - solitary violaceous nodules, 183
 - vascular papules and plaques, 180, 182
- Real-time polymerase chain reaction (PCR), 65
- Regulatory T cell, 108
- Rhabdomyosarcoma
 - adjuvant chemotherapy/radiation therapy, 163
 - alkylating agents/anthracycline, 164
 - atypical vascular tumor, 161
 - chest CT and bone scan, 164
 - crizotinib, 164
 - dermatology, 160
 - diagnosis, 162
 - differential diagnosis, 160
 - eroded exophytic nodule, 160, 161
 - ETV6-NTRK3 fusion gene, 163
 - fibrosarcoma, 162
 - hemangiomas, 163
 - herringbone pattern, 163
 - immunohistochemistry, 162
 - lungs and bone, 163
 - malignant tumors, 163
 - mesoblastic nephromas, 163
 - MRI, 161
 - physical examination, 160
 - vascular/lymphatic malformations, 162
 - ultrasound, kidneys and bladder, 161
- Rhizopus. *See* Disseminated systemic zygomycosis

S

- SACRAL syndrome, 181
- Salmon-pink coalescing macules and papules, 120, 121
- Salvage therapy, 112
- SCORTEN, 84
- Seborrheic dermatitis, 12
- Self-inflicted skin lesion (SISL), 202–204
- Serositis, 121
- Severe combined immunodeficiency (SCID), 12, 14
- Sexually transmitted infections (STIs), 197

- Sirolimus, 176, 186
- SJS/TEN
 - biopsy, 81
 - cell-death mediators, 83
 - clinical manifestations, 83
 - culprit drugs, 83
 - differential diagnosis, 82, 83
 - DRESS syndrome, 84
 - dysuria, 81
 - histopathology, 83
 - HLA-B1502, 83
 - laboratory, 81
 - mortality, 83
 - mycoplasma, 83
 - Nikolsky sign, 83
 - physical examination, 81
 - SCORTEN, 84
 - stringent wound care, 84
 - treatment, 85
 - trimethoprim-sulfamethoxazole, 81
 - vital signs, 81, 82
- Skeletal survey, 194, 196, 200
- Skin biopsy, 216
- Skin infections in children
 - blisters and fluid drainage, 41
 - bullous impetigo, 43
 - cellulitis, 48
- Skin signs, systemic diseases
 - panniculitis, 233–236
 - PG, 236–240
 - Sweet's syndrome, 229–233
- Skin, eye and mouth (SEM), 24
- Skin-directed therapy, 3
- Soak and smear method, 3
- Social services assessment, 200
- SSA/SSB antibody, 141
- Stage IV acute GVHD
 - diagnosis, 107
 - differential diagnosis, 107
 - ECP, 108, 109
 - focal tenderness, 106
 - IBMTR criteria, 107
 - lab investigation, 107
 - management, 108
 - methotrexate, 106
 - pediatric oncology, 106
 - physical examination, 106–107
 - prognosis, 109
 - skin biopsy, 107
 - skin discomfort, 106
 - treatment, 107–109
- Staph scalded skin syndrome (SSSS)
 - differential diagnosis, 42, 43

- Staph scalded skin syndrome (SSSS) (*cont.*)
 erythema and bullae formation, 42
 erythematous eruption, 41
 kidney function, 43
 laboratory parameters, 41–42
 methicillin-sensitive and methicillin-resistant strains, 42
 neonatal intensive care unit, 41
 physical exam, 41, 42
S. aureus, 42
 skin biopsy, 43
 skin condition, 42
 treatment, 42, 43
- Staphylococcal cassette chromosome (SSC), 48
- Staphylococcal infection, 8
- Staphylococcal scalded skin syndrome (SSSS), 83, 107
- Staphylococcal toxic shock syndrome, 43
- Staphylococcus aureus*, 11, 39, 40, 42, 46
- Steroid sparing immunosuppressive drugs, 223
- Stevens–Johnson syndrome (SJS), 28, 78, 107, 213
- Still's disease
 diagnosis, 121
 fever spikes, 119
 labs, 120
 physical exam, 120, 121
 SoJIA (*see* Systemic-onset juvenile idiopathic arthritis (SoJIA))
 workup and treatment(s), 121
- Streptococcal toxic shock syndrome (STSS), 40, 41
- Streptococcus pyogenes*, 39, 40, 46, 48
- Subcutaneous fat necrosis of the newborn (SCFN)
 diagnosis, 133
 epidemiology, 132
 focal/diffuse nodules, 133
 gestational diabetes and deep vein thrombosis, 132
 hypercalcemia, 133
 laboratory parameters, 132
 monitoring, 132, 134
 non-reassuring fetal heart, 132
 pathophysiology, 133
 physical examination, 132, 133
 risk factors, 132, 133
 treatment, 132, 134
- Subepidermal vesicle, 214
- Sweet's syndrome
 AML, 229, 232
 bilateral infra-orbital lesions, 230
 diagnostic criteria, 232
 differential diagnoses, 231
- G-CSF, 230
 investigations, 230–231
 medications, 232
 neutrophilic dermatoses, 232
 patient progress, 231
 physical examination, 230
 treatments, 231, 233
- Systemic lupus erythematosus (SLE)
 cutaneous manifestations, 124, 125
 diagnosis, 123, 124
 hands and cheeks, 123
 hematuria, 125
 hypertension, 125
 kidney biopsy, 125
 laboratory results, 123
 malar rash, 123
 multisystem disease, 123
 mycophenolate, 125
 physical examination, 123, 124
 proteinuria, 125
 quantitative measurement of proteinuria, 125
 treatment, 123, 125
- Systemic Lupus International Collaborating Clinic (SLICC) criteria, 124
- Systemic mycoses. *See* Disseminated systemic zygomycosis
- Systemic-onset juvenile idiopathic arthritis (SoJIA)
 diagnosis, 121, 122
 differential diagnosis, 122
 evanescent rash, 121
 generalized lymphadenopathy, 121
 hepatosplenomegaly, 121
 MAS, 122
 oncology and infectious disease, 122
 serositis, 121
 spiking fevers, 121
 treatment, 122
- T**
- T cell excision circles (TRECS), 12–14
- Teratogens, 136
- Terbinafine, 58
- Thermal burns, 200
- Tinea corporis, 57
- Topical CNI, 105
- Topical triamcinolone, 8
- Total skin electron beam (TSEB), 154
- Toxic epidermal necrolysis (TEN), 43, 78, 104, 106–108
- Toxic shock syndrome (TSS), 107
 causative organisms, 39

- course, 41
- diagnostic criteria, 40
- differential diagnosis, 39, 40
- laboratory parameters, 38–39
- morbidity, 41
- non-menstrual cases, 40
- physical examination, 38, 39
- staphylococcal and streptococcal superantigens, 39
- Staphylococcus aureus*, 39
- Streptococcus pyogenes*, 39
- STSS, 40
- symptoms, 38
- treatment, 39–41
- Toxic shock syndrome toxin-1 (TSST-1), 39
- Trauma-focused therapies, 195
- Trichophyton mentagrophytes, 58
- Trichophyton rubrum, 58
- Trichophyton violaceum, 58
- Trimethoprim-sulfamethoxazole, 62, 224
- Tumor lysis syndrome, 64, 152, 154
- Twin–twin perfusion syndrome, 150
- Tzanck staining, 56

U

- Ultraviolet A phototherapy (UVA), 112
- Urticaria multiforme
 - angioedema, 75
 - antecedent/concomitant viral illness, 75
 - differential diagnosis, 74
 - discoloration, 74, 75
 - dusky central clearing, 75
 - eosinophils, 76
 - laboratory, 74
 - pathogenesis, 75
 - physical examination, 74
 - serum sickness, 76
 - treatment, 76

V

- Vancomycin, 231
- Varicella zoster virus (VZV)
 - ALL, 26
 - diagnosis, 28
 - differential diagnosis, 28
 - immunocompetent and immunosuppressed patients, 26
 - linear crusted papulovesicles, 26, 27
 - management, 29
 - presentation, 27–28
 - prevention, 29
- Vascular anomalies
 - KHE, 174–176
 - LUMBAR syndrome, 179–181
 - multifocal vascular lesions, 184–186
 - RICH, 182–184
 - VM, 176–179
- Vasculitis
 - AHEI, 226, 227
 - HSP, 224–226
 - PAN, 221–223
- Venous malformation (VM)
 - D-dimer levels, 179
 - laboratory parameters, 177
 - LIC, 178
 - purple plaques, 177
 - subcutaneous fullness, 178
 - telangiectatic plaque, 177, 182
 - thrombosis, 179
 - treatment, 179
 - vascular proliferations, 178
 - X-ray, 178
- Von Willebrand (VW) disease, 193

W

- Wiskott–Aldrich syndrome, 12, 14

X

- X-linked agammaglobulinemia, 12